People with cancerous neuroendocrine tumors (NETs) that affect the digestive tract now have a new treatment option. On January 29, FDA approved the targeted treatment lutetium Lu 177 dotatate (Lutathera®) for adult patients with advanced NETs that affect the pancreas or gastrointestinal tract.
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2shUBvB
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου